Founded 1999 | ||
 | ||
Stock price ITEK (NASDAQ) US$ 1.70 +0.15 (+9.68%)10 Mar, 4:00 PM GMT-5 - Disclaimer Headquarters Lexington, Massachusetts, United States | ||
Inotek pharmaceuticals corp itek stock chart technical analysis for 01 03 17
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.
Contents
- Inotek pharmaceuticals corp itek stock chart technical analysis for 01 03 17
- Inotek pharmaceuticals ois aao 2015
- References
The Company's lead product candidate, trabodenoson (formerly known as INO-8875), is being evaluated for the treatment of elevated intraocular pressure associated with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG. Inotek is developing trabodenoson as a monotherapy delivered via eye drop, as well as a fixed-dose combination (FDC) with latanoprost, one of the leading current treatments for OHT and POAG.